Arcturus Therapeutics Holdings Inc. (ARCT) Bundle
An Overview of Arcturus Therapeutics Holdings Inc. (ARCT)
General Summary of Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage biopharmaceutical company focused on developing messenger RNA (mRNA) medicines for infectious diseases and rare diseases affecting the liver and respiratory system. The company was founded in 2013 and transitioned to a clinical stage in 2020. In 2023, Arcturus received marketing authorization for its COVID-19 vaccine, ARCT-154, known as KOSTAIVE®, in Japan, marking a significant milestone as the world’s first approved self-amplifying RNA (sa-mRNA) vaccine.
As of 2024, Arcturus is actively engaged in various clinical programs, including its LUNAR-CF program targeting cystic fibrosis and the LUNAR-OTC program for ornithine transcarbamylase deficiency. The company has established partnerships with leading organizations, including CSL Seqirus, to enhance its research and development capabilities.
In terms of sales, Arcturus anticipates generating revenue from KOSTAIVE® beginning in the fourth quarter of 2024, with significant potential from collaboration agreements and government contracts. The company has achieved approximately $462.1 million in upfront payments and milestones through its collaboration with CSL Seqirus.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, Arcturus reported total revenue of $129.5 million, a decrease of 4.7% compared to $135.9 million for the same period in 2023. The revenue primarily came from collaboration agreements, with $117.4 million from CSL Seqirus. In the third quarter of 2024, the company recorded revenue of $41.7 million, down from $45.1 million in the previous year, primarily due to lower milestone achievements.
| Financial Metric | 2024 (9 Months) | 2023 (9 Months) | Change (%) |
|---|---|---|---|
| Total Revenue | $129,544,000 | $135,944,000 | -4.7% |
| Operating Expenses | $191,819,000 | $195,877,000 | -2.1% |
| Net Loss | $(50,936,000) | $(18,018,000) | +182.5% |
| Cash and Cash Equivalents | $294,063,000 | $369,051,000 | -20.3% |
Operating expenses for the nine months ended September 30, 2024, were $191.8 million, a slight decrease from $195.9 million in the same period of 2023. The net loss for the same period was $(50.9) million, significantly higher than the $(18.0) million loss recorded in 2023.
Introduction to Company as One of the Leaders in the Industry
Arcturus Therapeutics is recognized as a leader in the mRNA therapeutics field, particularly following the successful launch of KOSTAIVE® in Japan. The company's proprietary LUNAR® and STARR® delivery platforms are at the forefront of innovation in mRNA technology, which positions Arcturus competitively within the biotechnology sector. The company continues to advance its clinical programs and explore new applications for its technologies, including potential vaccines for Lyme disease and gonorrhea.
With a strong pipeline and substantial collaboration agreements, Arcturus Therapeutics is poised for future growth and success within the rapidly evolving landscape of mRNA medicines.
Mission Statement of Arcturus Therapeutics Holdings Inc. (ARCT)
Mission Statement Overview
Arcturus Therapeutics Holdings Inc. (ARCT) has articulated a mission statement centered on advancing the development of messenger RNA (mRNA) medicines, particularly in the realms of infectious diseases and rare genetic disorders. The significance of this mission lies in its role as a guiding principle for the company's long-term objectives, focusing on innovation, safety, and accessibility in healthcare solutions.
Core Component 1: Innovation
Innovation is a cornerstone of Arcturus Therapeutics' mission. The company is dedicated to leveraging its proprietary technologies, including the STARR® (Self-Amplifying RNA) platform and LUNAR® lipid-mediated delivery system, to create next-generation vaccines and therapeutics. For instance, the ARCT-154 vaccine, also known as KOSTAIVE®, became the world’s first approved self-amplifying RNA vaccine in September 2024, reflecting the company's commitment to groundbreaking advancements in mRNA technology.
Core Component 2: Commitment to Quality
Arcturus emphasizes a strong commitment to quality in its product development and manufacturing processes. This commitment is supported by significant financial investments in research and development, which totaled approximately $151.4 million for the nine months ended September 30, 2024. The company’s stringent quality assurance protocols are designed to ensure that its products meet the highest safety and efficacy standards, fostering trust among stakeholders and patients alike.
Core Component 3: Accessibility
Accessibility is a vital element of Arcturus' mission statement. The company aims to make its innovative mRNA therapies available to a broad patient population. Through strategic collaborations, such as the agreement with CSL Seqirus, Arcturus is positioned to scale production and distribution effectively. The CSL Collaboration Agreement includes potential milestones exceeding $1.3 billion, which underscores the financial backing available to enhance accessibility. Furthermore, the company aims to address unmet medical needs, particularly in the fields of infectious diseases and rare genetic disorders, ensuring that its breakthroughs reach those who need them most.
| Financial Data (as of September 30, 2024) | Value (in thousands) |
|---|---|
| Cash and Cash Equivalents | $237,178 |
| Restricted Cash | $55,000 |
| Accounts Receivable | $30,199 |
| Total Revenue | $129,544 |
| Research and Development Expenses | $151,376 |
| Net Loss | $50,936 |
| Accumulated Deficit | $418,802 |
The financial data presented in the table illustrates Arcturus' operational scale and the investment in its mission, highlighting the resources allocated towards innovation, quality, and accessibility for mRNA therapies.
Vision Statement of Arcturus Therapeutics Holdings Inc. (ARCT)
Vision Statement Overview
The vision statement of Arcturus Therapeutics Holdings Inc. (ARCT) focuses on leveraging its innovative mRNA technologies to address critical healthcare needs, particularly in the fields of infectious diseases and rare genetic disorders. As of 2024, Arcturus aims to be a leader in the development of mRNA-based vaccines and therapeutics that significantly improve patient outcomes globally.
Commitment to Innovation
Arcturus is dedicated to advancing its proprietary technologies, including the LUNAR® platform and STARR® technology. These innovations are designed to enhance the safety, efficacy, and delivery of mRNA therapeutics. In 2024, Arcturus has made significant strides, including:
- Achieving marketing authorization for its COVID-19 vaccine, ARCT-154 (KOSTAIVE®), in Japan.
- Being the first company to commercialize a self-amplifying RNA vaccine.
- Investing in research and development to expand its pipeline of mRNA-based solutions.
Global Health Impact
Arcturus aims to play a pivotal role in global health by providing innovative solutions for infectious diseases and rare genetic conditions. The company has established partnerships to enhance its reach and impact:
- Collaboration with CSL Seqirus for mRNA vaccine development, which includes a potential total of over $3 billion in commercial milestones based on net sales.
- Partnership with the Biomedical Advanced Research and Development Authority (BARDA) for up to $63.2 million in funding to support vaccine development efforts.
Financial Strength and Resource Allocation
As of September 30, 2024, Arcturus reported:
| Financial Metric | Value (in thousands) |
|---|---|
| Cash and Cash Equivalents | $237,178 |
| Restricted Cash | $55,000 |
| Total Assets | $370,654 |
| Accumulated Deficit | $(418,802) |
| Net Loss (Nine Months Ended Sept 30, 2024) | $(50,936) |
These figures reflect the company's strategic focus on investing in its development pipeline while maintaining a robust financial position to support ongoing and future projects.
Future Aspirations
Looking ahead, Arcturus aims to:
- Expand its vaccine portfolio to include candidates for Lyme disease and gonorrhea.
- Continue enhancing its LUNAR platform to improve delivery mechanisms for mRNA therapeutics.
- Achieve regulatory approvals and commercial success for its pipeline products, thereby solidifying its position as a leader in mRNA technology.
Core Values of Arcturus Therapeutics Holdings Inc. (ARCT)
Integrity
Integrity is foundational to Arcturus Therapeutics Holdings Inc.'s operations as of 2024. This core value emphasizes honesty and transparency in all dealings, both internally and externally.
Arcturus has demonstrated its commitment to integrity through its rigorous compliance with regulatory standards and ethical practices in clinical trials. For instance, the company has achieved compliance with the FDA and EMA regulations during the development of its COVID-19 vaccine, ARCT-154, which received marketing authorization in Japan in 2023 and became the first commercially available self-amplifying RNA vaccine in September 2024 .
Innovation
Innovation is at the heart of Arcturus's mission to develop cutting-edge mRNA therapeutics. The company is dedicated to leveraging its proprietary LUNAR® and STARR® platforms to create more effective vaccines and therapies.
As of September 2024, Arcturus initiated new vaccine discovery programs for Lyme disease and gonorrhea, utilizing its advanced mRNA technology that has shown superior immunogenicity compared to conventional vaccines . The collaboration with CSL Seqirus also highlights Arcturus's innovative approach, aiming to develop a safe and effective seasonal influenza vaccine candidate using its mRNA platform .
Collaboration
Collaboration is crucial for Arcturus, enabling the company to expand its reach and enhance its capabilities. The partnership with CSL Seqirus exemplifies this core value, providing exclusive global rights to research and develop mRNA vaccines against several infectious diseases.
Through this collaboration, Arcturus has secured approximately $462.1 million in upfront payments and milestones, including a $25 million milestone achieved in the third quarter of 2024 . This strategic alliance not only enhances Arcturus's financial position but also accelerates the development of innovative vaccines .
Excellence
Excellence drives Arcturus to maintain high standards in its research and operational practices. The company invests significantly in research and development to ensure the efficacy and safety of its products.
In the nine months ended September 30, 2024, Arcturus reported total revenue of $129.5 million, showcasing its commitment to delivering high-quality therapeutic solutions . Additionally, the company has made significant advancements in its LUNAR technology, improving the delivery of mRNA therapeutics .
Accountability
Accountability ensures that Arcturus takes responsibility for its actions and decisions. The company maintains transparency with its stakeholders regarding its financial performance and operational challenges.
As of September 30, 2024, Arcturus reported an accumulated deficit of $418.8 million, reflecting the challenges faced while pursuing innovative therapies . The company continues to communicate openly about its financial status and future funding requirements, ensuring stakeholders are informed of its progress and hurdles .
| Core Value | Description | Examples | Financial Impact |
|---|---|---|---|
| Integrity | Emphasizes honesty and transparency in operations. | Compliance with FDA and EMA regulations. | Marketing authorization for ARCT-154; first sa-mRNA vaccine . |
| Innovation | Focus on developing cutting-edge therapeutics. | New vaccine programs for Lyme disease and gonorrhea. | Increased R&D investment; $129.5 million revenue . |
| Collaboration | Partnerships that enhance capabilities. | Collaboration with CSL Seqirus. | $462.1 million in milestones . |
| Excellence | Maintaining high standards in R&D. | Advancements in LUNAR technology. | Financial growth; significant revenue generation . |
| Accountability | Responsibility for actions and decisions. | Transparent communication with stakeholders. | Reported accumulated deficit of $418.8 million . |
Arcturus Therapeutics Holdings Inc. (ARCT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Arcturus Therapeutics Holdings Inc. (ARCT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Arcturus Therapeutics Holdings Inc. (ARCT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.